ARQT Arcutis Biotherapeutics
- 8.150
- +0.190+2.39%
- 8.100
- -0.050-0.61%
Arcutis Biotherapeutics News
Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?
Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 99.89%: Read This Before Placing a Bet
FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D
Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug
Sector Update: Health Care Stocks Mixed Premarket Tuesday
Health care stocks were mixed premarket Tuesday, with the Health Care Select Sector SPDR Fund (XLV) was 0.1% higher and the iShares Biotechnology ETF (IBB) was down 0.5% recently. Viridian Therapeutic
Arcutis Biotherapeutics Says Experimental Cream Showed Improvements in Atopic Dermatitis Symptoms
Arcutis Biotherapeutics (ARQT) said Monday its experimental roflumilast cream 0.15% showed continued improvements in the signs and symptoms of atopic dermatitis, including itch, through 56 weeks of tr
Express News | Arcutis Biotherapeutics Inc: Once-Daily, Roflumilast Cream 0.15% Was Well Tolerated
Express News | Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (Ad) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
Arcutis Biotherapeutics(ARQT.US) Director Sells US$80,091.7 in Common Stock
$Arcutis Biotherapeutics(ARQT.US)$ Director Welgus Howard G. sold 10,000 shares of common stock on Jun 4, 2024 at an average price of $8.0092 for a total value of $80,091.7.Source: Announcement What i
Amgen's (AMGN) Uplizna Meets Study Goal for Rare Disease
AbbVie (ABBV) Starts Late-Stage Study on Multiple Myeloma Drug
Press Release: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WESTLAKE VILLAGE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a comm
Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
New long-term safety and efficacy data of investigational roflumilast cream 0.15% in mild to moderate atopic dermatitis will be presented in an oral sessionPreclinical data on ARQ-234, CD200R agonist,
Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
WESTLAKE VILLAGE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in
Arcutis Biotherapeutics(ARQT.US) Officer Sells US$636.71K in Common Stock
$Arcutis Biotherapeutics(ARQT.US)$ Officer Burnett Patrick sold 72,952 shares of common stock on May 29, 30, 2024 at an average price of $8.7277 for a total value of $636.71K.Source: Announcement What
Form 144 | Arcutis Biotherapeutics(ARQT.US) Officer Proposes to Sell 201.32K in Common Stocks
SEC FILLINGS DISCLOSED/ May 30, $Arcutis Biotherapeutics(ARQT.US)$ Officer Burnett Patrick intends to sell 23,000 shares of its common stock on May 30, with a total market value of approximately $201.
J&J's (JNJ) Oral Pill Improves Depression & Insomnia Symptoms
Form 144 | Arcutis Biotherapeutics(ARQT.US) Officer Proposes to Sell 435.38K in Common Stocks
SEC FILLINGS DISCLOSED/ May 29, $Arcutis Biotherapeutics(ARQT.US)$ Officer Burnett Patrick intends to sell 49,952 shares of its common stock on May 29, with a total market value of approximately $435.
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Soars on Dermatological Treatments Launch
Analysis
Price Target
No Data
